Jones Financial Companies Lllp Purchases 748 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jones Financial Companies Lllp raised its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 195.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,130 shares of the medical device company’s stock after acquiring an additional 748 shares during the quarter. Jones Financial Companies Lllp’s holdings in Tandem Diabetes Care were worth $41,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of TNDM. Baillie Gifford & Co. lifted its holdings in shares of Tandem Diabetes Care by 235.7% during the fourth quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock valued at $26,875,000 after purchasing an additional 523,843 shares during the last quarter. GW&K Investment Management LLC lifted its holdings in shares of Tandem Diabetes Care by 18.0% during the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock valued at $76,488,000 after purchasing an additional 323,674 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of Tandem Diabetes Care by 19.9% during the third quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company’s stock valued at $78,496,000 after purchasing an additional 307,624 shares during the last quarter. Stephens Investment Management Group LLC lifted its holdings in shares of Tandem Diabetes Care by 22.1% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company’s stock valued at $56,040,000 after purchasing an additional 281,327 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Tandem Diabetes Care by 397.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company’s stock valued at $11,121,000 after purchasing an additional 240,966 shares during the last quarter.

Insider Buying and Selling

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the company’s stock in a transaction on Friday, March 7th. The stock was acquired at an average price of $18.12 per share, with a total value of $190,948.56. Following the acquisition, the chief operating officer now directly owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 2.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on TNDM shares. Morgan Stanley lowered shares of Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $45.00 to $22.00 in a report on Wednesday, March 5th. Barclays decreased their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a report on Friday, February 28th. The Goldman Sachs Group decreased their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Royal Bank of Canada decreased their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Finally, Citigroup lowered shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $24.00 in a report on Tuesday, March 4th. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $45.38.

Tandem Diabetes Care Trading Up 1.8 %

Shares of Tandem Diabetes Care stock opened at $20.06 on Wednesday. The company has a market capitalization of $1.33 billion, a P/E ratio of -10.39 and a beta of 1.45. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company has a fifty day moving average of $30.69 and a 200 day moving average of $34.21. Tandem Diabetes Care, Inc. has a fifty-two week low of $17.64 and a fifty-two week high of $53.69.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.